OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT...
Transcript of OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT...
![Page 1: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/1.jpg)
OVERVIEW OF PARKINSON’S DISEASE TREATMENT
OPTIONS
Delaram Safarpour, MD MSCE
Assistant Professor of Neurology
OHSU Parkinson Center
July, 19th, 2018
![Page 2: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/2.jpg)
OVERVIEW
• Common classes of medications
• Common side effects
• What new therapies to expect in the coming years
• What therapies beside medication?
![Page 3: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/3.jpg)
WHAT ARE THE TREATMENT OPTIONS?
Medications
Surgical
Exercise
Healthy diet Mindfulness
![Page 4: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/4.jpg)
MEDICINE
• Carbidopa/levodopa (Sinemet, Rytary)
• Dopamine Agonists (pramipexole, ropinirole)
• COMT-inhibitors (entacapone)
• MAO-I’s (selegiline, rasagiline)
![Page 5: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/5.jpg)
LEVODOPA – “OLDIE BUT GOODIE”
• Also known as.. • Carbidopa-Levodopa • Sinemet • L-dopa
• FDA Approved over 35 years ago • Still the strongest medicine • Still the safest, best tolerated
![Page 6: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/6.jpg)
LEVODOPA
• How does it work?
• Brain converts it into Dopamine
• So, restores some of the supply of dopamine to the brain
• Restores some of the dopamine signal to get moving again
![Page 7: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/7.jpg)
SIDE EFFECTS
• Nausea
• Fatigue
• Visual hallucination, illusions
• Dyskinesias (extra movements)
• Orthostatic hypotension (low blood pressure when standing)
• Cognitive changes
![Page 8: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/8.jpg)
RYTARY: (NOT A NEW DRUG! BUT A NEW WAY TO DELIVER AN OLD DRUG!)
![Page 9: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/9.jpg)
RYTARY:
Indications:
• Significant on- off times or dyskinesia
• Frequent dosing of Sinemet (carbidopa-levodopa)
• Morning off symptoms
Important to know that Rytary is the same as C/L but stays in blood for a longer time (4-5 hrs)
![Page 10: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/10.jpg)
SIDE EFFECTS:
• Nausea
• Orthostatic hypotension
• Hallucinations and delusions
![Page 11: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/11.jpg)
DOPAMINE AGONISTS
• Pramipexole (Mirapex)
• Ropinirole (ReQuip)
• Apomorphine (Apokyn), “rescue”
• Rotigotine (Neupro), “the patch”
![Page 12: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/12.jpg)
AGONISTS
• How do they work?
• Is not converted to dopamine
• Instead, it acts like dopamine
• Directly activates the part of the brain that starts that signal to get moving.
![Page 13: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/13.jpg)
AGONISTS ADVANTAGES (+)
• Longer acting, smoother response
• Less ups and downs (Fluctuations)
• Less extra movements (dyskinesias)
• Helpful in early PD, in younger patients
• Helpful as adjunct (boost) to Levodopa
![Page 14: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/14.jpg)
AGONIST DISADVANTAGES (-)
• Not as strong as levodopa
• More side effects • Sleepiness, hallucinations, lightheadedness, nausea, ankle
swelling
• Impulse control problems (gambling, shopping, eating, internet).
• Less helpful in more advanced PD, older patients
![Page 15: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/15.jpg)
AGONISTS
• Apomorphine (Apokyn)
• Injected under the skin
• Rapid-onset (about 10 minutes) so can help “rescue” from sudden off’s, severe freezing
• Side effects: nausea/vomiting, low blood pressure
![Page 16: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/16.jpg)
AGONISTS
• Rotigotine (Neupro Patch)
• (+) Easy patch system
• (+) Once a day
• Works same as pramipexole, ropinirole
• If pramipexole and ropinirole work well but you have symptoms in between… patch is a good choice!
![Page 17: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/17.jpg)
LEVODOPA VS. THE AGONISTS THE BIG QUESTIONS
• Do the agonists prevent dyskinesias?
• Does levodopa cause dyskinesias and fluctuations?
• Do the agonists protect brain cells?
• Is Levodopa toxic?
• Is there tolerance to levodopa? (Will it only work for so long?)
![Page 18: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/18.jpg)
LEVODOPA VS. THE AGONISTS ANSWERS
• The focus of lots of research
• Levodopa has more dyskinesias, but does not quicken onset
• Levodopa not thought to be toxic
• Actually better survival with treatment
• Best answer is to treat each person individually
![Page 19: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/19.jpg)
COMT-INHIBITORS
• Entacapone (Comtan) :
• Works by blocking breakdown of levodopa
• Levodopa stays around longer
• Stalevo (Entacapone + Levodopa):
• Just helps by taking less pills
![Page 20: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/20.jpg)
MAO-INHIBITORS
• Selegiline (Eldepryl) - older
• Rasagiline (Azilect) – 2006
• Also works by blocking breakdown of dopamine
• ??? Neuroprotective
• Mild effect on symptoms
![Page 21: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/21.jpg)
OTHER MEDS
• Amantadine, helps reduce dyskinesias, and mildly helps PD symptoms, 2-3 times a day
• Amantadine ER ( Gocovri), once at night formulation, FDA approved for dyskinesia , reduces off time symptoms
• Amantadine ER (Osmolex), for off time symptoms, not approved for dyskinesia, once a day
• Artane and Cogentin, both decrease tremor, but have lots of side effects (mainly sleepiness)
![Page 22: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/22.jpg)
XADAGO ( SAFINAMIDE)
• Approved in 2017 as an add on treatment.
( should be taken together with sinemet)
• Improves on time without worsening dyskinesia.
• Blocks MAOB enzyme that breaks down dopamine, therefore increases dopamine availability in the brain
• Possible side effects: dyskinesia, falls, nausea, insomnia
![Page 23: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/23.jpg)
WHAT IS COMING DOWN THE PIPE LINE?!
![Page 24: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/24.jpg)
CONTINUOUS APOMORPHINE • Subcutaneous infusion of apomorphine
• Normally used as a 16-h daytime treatment, but can be given over 24 h in the case the patient needs night-time effect.
• Pros: reduces “off” time, No need for surgery
• Con’s: needle should be changed daily, can cause skin breakdown and accesses, requires co treatment with anti nausea medication.
![Page 25: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/25.jpg)
LEVODOPA PATCH • ND0612: continuous subcutaneous delivery
through a custom patch pump
• Pump patch: size of a credit card
• Belt pump: reservoir in small pump
• Drug stored in reservoir and pumped through skin through micro-needles into the blood stream
• 24 hour infusion
![Page 26: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/26.jpg)
XP 21279 • L-dopa prodrug (changes to Levodopa after absorption)
• What is good about this?
- Absorbed everywhere in the GI tract
![Page 27: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/27.jpg)
XP 21279
• Decrease OFF time without increasing dyskinesias
• Decrease dosing frequency
• The long length of colon provides extra absorption that helps with a more steady dose of medication in blood
![Page 28: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/28.jpg)
MELEVODOPA
• Liquid formulation
• What is good about this?
-Absorbed more rapidly than usual CD/LD formulation
![Page 29: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/29.jpg)
INHALED FORMULATION
• CVT-301:
inhaled formulation of L-dopa to treat OFF episodes
• Results:
• Improvement in movements scores Reduced daily OFF time
t
![Page 30: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/30.jpg)
COMT INHIBITORS
• Opicapone: Entacapone family
• What is good about this?
• Once daily dosing
• Decreases OFF time and increased ON time w/o troublesome dyskinesia
• Just as good as entacapone!
![Page 31: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/31.jpg)
CAFFEINE
• May reduce dyskinesia
• Self reported caffeine consumption higher than 12oz/day was associated with less frequent dyskinesia as compared with consumers of less than 4oz/day
![Page 32: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/32.jpg)
DUODOPA • Continuous infusion of
carbidopa/levodopa through PEG tube
![Page 33: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/33.jpg)
DUODOPA • What is good about this?
1. No more pills
2. Continuous infusion throughout the day will provide a more steady state
3. If for any reason you are not a candidate for DBS or do not want to go through brain surgery…
![Page 34: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/34.jpg)
DUODOPA
• What is NOT so good about this?
1. The cassette is not very light/small
2. You should keep the PEG site clean to avoid infections
![Page 35: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/35.jpg)
COMMON QUESTIONS: • What are the possible side effects of Duopa?
Complications of device insertion
Abdominal pain
Procedure pain
Nausea
Excessive granulation tissue
Most of these side effects are rare, especially with good care before and after the surgery and an expert surgical team
![Page 36: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/36.jpg)
NON-PHARMACOLOGIC TREATMENTS
• Nutrition- balanced diet, protein intake, weight loss
• Exercise- Physical therapy for gait impairment, balance
• Speech therapy and swallowing therapy • Cognitive therapy through speech or OT
• Support- home health aides, day cares, support groups
• Psychiatric care – can be the most difficult part, but has many effective treatments
![Page 37: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/37.jpg)
SUMMERY POINTS
• There are several different classes of medications
• Its common to use combination of different classes
• Therapy is tailored to manage individual patient’s symptoms
• We can just treat the symptoms, can’t cure the disease
• It is best to use benefit of non medical approaches as well.
![Page 38: OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS · OVERVIEW OF PARKINSON’S DISEASE TREATMENT OPTIONS . Delaram Safarpour, MD MSCE . Assistant Professor of Neurology . OHSU Parkinson](https://reader033.fdocuments.net/reader033/viewer/2022041511/5e2819688894751f6a2c5bfe/html5/thumbnails/38.jpg)
•Thank you